Saving changes...

Done

Error

Hepatitis C Module #4: Treatment of HCV in Special Populations, HCV Resistance, and the Future of HCV Therapy

Hepatitis C Module #4: Treatment of HCV in Special Populations, HCV Resistance, and the Future of HCV Therapy

Hepatitis C Module #4: Treatment of HCV in Special Populations, HCV Resistance, and the Future of HCV Therapy

Autumn D. Bagwell, PharmD, BCPS, AAVHIP, Paulina Deming, PharmD
Autumn D. Bagwell, PharmD, BCPS, AAVHIP, Paulina Deming, PharmD
on behalf of ProCE Inc.

FREE
FREE
FREE

FREE
FREE
FREE

null FREE
FREE
FREE
null FREE
FREE
FREE
Normal Price: FREE FREE

Review:

Launch date: 08 Mar 2017
Expiry Date:

Last updated: 13 Mar 2017

Reference: 170925

This course is no longer available

Exam is embedded in the course
No preview available
No Exam Available

Latest User Comments

I would like to...

Course Availability

This course is only available to trainees days after purchase. It would need to be repurchased by the trainee if not completed in the allotted time period. This course is no longer available. You will need to repurchase if you wish to take the course again.

You have null days left.

Description

Hepatitis C virus (HCV) has become one of the most common infections worldwide. According to the CDC, up to 3.9 million people in the United States may be infected. Healthcare costs associated with this disease have been climbing steadily to make it one of the costliest diseases to treat. Individuals infected with this contagious virus can remain asymptomatic for many years until HCV manifests into a serious clinical presentation. The disease can be acute or chronic ranging from mild to life threating in severity. This comprehensive four module program will provide a complete overview of HCV including disease state info, treatments, therapy selection, monitoring, and future considerations. Module Four will include appropriateness of therapy for special populations, resistance issues, and emerging treatment options. The role of the specialty pharmacist will also be addressed.

Objectives

Objectives
Learning Objectives:The target audience for this activity includes pharmacists. Upon completion of this activity, participants will be able to:Outline variables to consider when assessing appropriateness of HCV therapy in patients with HIV, renal insufficiency, decompensated liver disease or liver transplant.Describe common resistance features in HCV.Compare and contrast emerging HCV therapies.Describe the role of specialty pharmacists in the management of special populations and collaborations with the healthcare team.
Autumn D. Bagwell, PharmD, BCPS, AAVHIP, Paulina Deming, PharmD

Author Information Play Video Bio

Autumn D. Bagwell, PharmD, BCPS, AAVHIP, Paulina Deming, PharmD
on behalf of ProCE Inc.

Autumn D. Bagwell, PharmD, BCPS, AAVHIP Clinical Pharmacy Specialist: Infectious Diseases Vanderbilt University Specialty Pharmacy Nashville, TennesseePaulina Deming, PharmD Associate Professor of Pharmacy Clinical Pharmacist, UNMH Hepatitis C Clinic The University of New Mexico Health Sciences Center Albuquerque, New Mexico

Current Accreditations

This course has been certified by or provided by the following Certified Organization/s:

  • Accreditation Council for Pharmacy Education (ACPE)
  • 1.20 Hours -
    Exam Pass Rate: 75
    -
    Reference: 0221-9999-17-080-H01-P

Faculty and Disclosures

Additional Contributors

null

Conflicts Declared

Conflicts of Interest declaration by Author:

null

User Reviews (0)

Go Back

Loading...


Saving changes...

Done

Error